Eventide Asset Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Eventide Asset Management’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-13,000	Closed	-$1.6M	–	131
2017 Q1	$1.6M	Sell	13,000 -12,000	-48%	-$1.57M	0.11%	96
2016 Q4	$3.4M	Buy	+25,000	New	+$4.44M	0.22%	80

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Eventide Asset Management's BLCM Position: Q2 2017 in Review

Eventide Asset Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2017, closing a stake of 13,000 shares — an estimated $1.6M sold.

Eventide Asset Management first reported a position in BLCM in Q4 2016 and held it in 2 quarters. The position peaked at $3.4M in Q4 2016. 84 funds tracked by Wall St. Rank hold BLCM as of Q2 2017.

Eventide Asset Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
Eventide Asset Management sold 13,000 Bellicum Pharmaceuticals, Inc. shares in Q2 2017, an estimated $1.6M.
Eventide Asset Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2016 and held it in 2 quarters.
Eventide Asset Management's Bellicum Pharmaceuticals, Inc. position peaked at $3.4M in Q4 2016.
84 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2017.

Based on Eventide Asset Management's 13F filing for Q2 2017, filed 14 Aug 2017.